Feature

Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief


 

By the time Ann Marie Owen turned to marijuana to treat her pain, she was struggling to walk and talk. She also hallucinated.

For 4 years, her doctor prescribed the 61-year-old a wide range of opioids for her transverse myelitis, a debilitating disease that caused pain, muscle weakness, and paralysis.

Medical marijuana leaves are shown. Courtesy Wikimedia Commons/Coaster420/Creative Commons License

The drugs not only failed to ease her symptoms, they also hooked her.

When her home state of New York legalized marijuana for the treatment of select medical ailments, Ms. Owens decided it was time to swap pills for pot. But her doctors refused to help.

“Even though medical marijuana is legal, none of my doctors were willing to talk to me about it,” she said. “They just kept telling me to take opioids.”

While 29 states have legalized marijuana to treat pain and other ailments, the growing number of Americans like Ms. Owen who use marijuana and the doctors who treat them are caught in the middle of a conflict in federal and state laws – a predicament that is only worsened by thin scientific data.

Because the federal government classifies marijuana a Schedule 1 drug – by definition a substance with no currently accepted medical use and a high potential for abuse – research on marijuana or its active ingredients is highly restricted and even discouraged in some cases.

Pages

Recommended Reading

Nonopioid analgesics have no major disadvantages vs. opioids for chronic pain
MDedge Rheumatology
Opioid prescriptions got shorter in 2017
MDedge Rheumatology
The case for being open-minded about medical marijuana
MDedge Rheumatology
Intramuscular steroid injection reduced hip OA pain up to 12 weeks
MDedge Rheumatology
MDedge Daily News: Why the barber’s chair can help hypertension
MDedge Rheumatology
Is kratom the answer to the opioid crisis?
MDedge Rheumatology
FDA recalls kratom products for salmonella contamination
MDedge Rheumatology
MDedge Daily News: Does more marijuana mean fewer opioids?
MDedge Rheumatology
CMS finalizes measures to help combat opioid crisis
MDedge Rheumatology
Life and health are not even across the U.S.
MDedge Rheumatology